News | Breast Imaging | August 19, 2022

One of the Cincinnati Region’s top doctors turns to groundbreaking technology to help ensure a better overall experience for breast cancer patients

The Molli device features the smallest localization marker on the market that precisely marks where tumors are located prior to breast cancer surgery, helping the surgeon remove them more efficiently and improving the patient’s overall experience

August 19, 2022 —  The Christ Hospital Health Network, known for providing the best, most compassionate care for its community, is the first in Ohio to adopt Molli Surgical’s wire-free and radiation-free breast cancer localization technology: Molli. The Molli device features the smallest localization marker on the market that precisely marks where tumors are located prior to breast cancer surgery, helping the surgeon remove them more efficiently and improving the patient’s overall experience.  

The Christ Hospital Health Network’s adoption of this technology reflects its commitment to doing everything it takes for patients, such as driving innovations like wire-free localization that improve the patient experience. Going forward, Molli Surgical will be the provider of wire-free, radiation-free technology for breast surgery. 

"Marking the tumor for those needing breast cancer surgery can be a difficult experience for the patient — typically using a wire on the same day of surgery. Molli decouples localization from surgery, providing more flexibility for the patient,” says Jennifer B. Manders, MD. “Plus, the device is easy-to-use, efficient, and extremely precise. We chose Molli after testing other wire-free and radiation-free devices as it had proven to deliver superior results and benefits for the patient, the radiologist, and the surgeon.” 

“Like ourselves, the team at The Christ Hospital Health Network is dedicated to reimagining what healthcare can be and truly understanding patient-first care,” said Fazila Seker, Ph.D., President, and CEO of Molli Surgical Inc. “We are committed to helping them create more efficiencies in their radiology and surgery departments and deliver exceptional outcomes and experiences for their patients.” 

Molli Surgical’s FDA-cleared Molli allows surgeons to pinpoint cancerous tissue for faster, more accurate, and less painful tumor removal, offering an improved experience and better cosmetic outcomes for breast cancer patients, as well as patients living with different types of cancers. The wire-free technology includes the Molli Marker, about the size of a sesame seed, that can be detected using the Molli Wand and the Molli Tablet.  

For more information: mollisurgical.com 


Related Content

News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
Subscribe Now